CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-15 | Mohindru Mani Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2024-05-15 | Meyers James R Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2024-05-15 | Jones Elaine V Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2024-05-15 | Gilbert Halley E Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2024-05-15 | Ashworth Alan Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2024-03-26 | McCarthy Sean A. CEO | Option exercise | +109,768 | $1.57 | $173K | 634,249 |
| 2024-03-26 | McCarthy Sean A. CEO | Option exercise · Stock Option (Right to Buy) | −109,768 | 0 | ||
| 2024-03-20 | Su Zhen Director | Grant or award · Stock Option (Right to Buy) | +76,000 | 76,000 | ||
| 2024-03-19 | ROWLAND LLOYD A General Counsel | Sale | −5,268 | $2.09 | $11K | 117,728 |
| 2024-03-19 | McCarthy Sean A. CEO | Sale | −20,223 | $2.09 | $42K | 524,481 |
| 2024-03-19 | Ogden Christopher SVP, Finance and Accounting | Sale | −2,971 | $2.09 | $6K | 85,686 |
| 2024-03-19 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −12,795 | $2.09 | $27K | 168,579 |
| 2024-03-19 | Landau Jeffrey B Chief Business Officer | Sale | −6,562 | $2.09 | $14K | 110,060 |
| 2024-01-18 | McCarthy Sean A. CEO | Grant or award | +90,000 | 544,704 | ||
| 2024-01-18 | McCarthy Sean A. CEO | Grant or award · Stock Option (Right to Buy) | +420,000 | 420,000 | ||
| 2024-01-18 | McCarthy Sean A. CEO | Grant or award · Performance Stock Units (PSUs) | +260,000 | 260,000 | ||
| 2024-01-18 | ROWLAND LLOYD A General Counsel | Grant or award | +25,000 | 122,996 | ||
| 2024-01-18 | ROWLAND LLOYD A General Counsel | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-01-18 | ROWLAND LLOYD A General Counsel | Grant or award · Performance Stock Units (PSUs) | +75,000 | 75,000 | ||
| 2024-01-18 | Ogden Christopher SVP, Finance and Accounting | Grant or award | +40,000 | 88,657 |
Page 6 of 33 · 649 trades